Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
1h
Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
FiercePharma
20h
With BIOSECURE in limbo, should BeiGene or Legend sell itself in 2025? Analysts weigh in
When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
CA fires death toll rises
California fires: How to help
Singer Anita Bryant dies
'Pizzagate' gunman killed
Must face defamation suit
Judge scraps Title IX rules
Sues over ‘Rust' prosecution
Freed after brief detention
1.2M-year-old ice core
La Nina finally arrives
Presidential palace attack
Sworn in as NH governor
Economic growth forecast
SCOTUS rejects Trump’s bid
Peacock president to exit
Wycheck had CTE
Court allows report release
Crime leader pleads guilty
Lebanon's new president
Ski patrol strike ends
Clarifies Siri privacy stance
Appeals her disqualification
ACLU sues DeSantis
Oscar nominations delayed
Bill to sanction ICC OK'd
US settles w/ Johns Hopkins
Santos' sentencing delayed
EC fined for data breach
Settles opioid lawsuit
Related topics
WuXi
United States
Merck & Co.
Republic of Ireland
Feedback